These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32377764)

  • 21. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
    Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
    Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of radiolabeled PSMA ligands for tumor imaging.
    Shahrokhi P; Masteri Farahani A; Tamaddondar M; Rezazadeh F
    Chem Biol Drug Des; 2022 Jan; 99(1):136-161. PubMed ID: 34472217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
    Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
    Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
    Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
    Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
    Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific Membrane Antigen: Diagnostics.
    Alberts IL; Seifert R; Werner RA; Rowe SP; Afshar-Oromieh A
    PET Clin; 2024 Jul; 19(3):351-362. PubMed ID: 38702228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives.
    Lin M; Ta RT; Kairemo K; Le DB; Ravizzini GC
    Cancer Biother Radiopharm; 2021 Apr; 36(3):237-251. PubMed ID: 32589458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T; Gschwend JE; Eiber M
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
    Koschel S; Murphy DG; Hofman MS; Wong LM
    Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
    J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
    Cytawa W; Hartrampf P; Lass P; Kircher M; Polat B; Buck AK; Lapa C
    Clin Genitourin Cancer; 2021 Aug; 19(4):e235-e247. PubMed ID: 33906800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
    Emmett L
    Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.